12:00 AM
 | 
Jun 24, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ImMucin: Additional Phase I/II data

Additional data from the open-label, Israeli Phase I/II VAXIL-001 trial in 15 patients experiencing a gradual re-emergence of MUC1-positive MM after a period of remission attained by autologous stem cell transplant (ASCT) showed that ImMucin led to 5 complete responses plus...

Read the full 185 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >